Work

Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma

Year: 2011

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-11-1747

Authors: Kevin B. Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael M. Shi, John M. Kirkwood

Institutions: The University of Texas MD Anderson Cancer Center, University of Louisville, University of Pittsburgh, Novartis (United States), UPMC Hillman Cancer Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2050328756

FWCI: 6.083

Cites: 49

Cited by: 120

Related to: 10